On December 14, 2021 JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, reported the primary clinical response on Carteyva (relmacabtagene autoleucel injection) in adults with relapsed/refractory follicular lymphoma (r/r FL) in China at the 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (Press release, JW Therapeutics, DEC 14, 2021, View Source [SID1234597151]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As of the data cut-off of September 10, 2021, 28 patients were treated with Carteyva with at least three months of follow-up.
Of 27 efficacy evaluable patients, as assessed by the investigator, best overall response rate (ORR) was 100% (27/27) and best complete response rate (CRR) was 92.6% (25/27). With a median follow-up of 8.84 months, the median duration of response (DOR), progression-free survival (PFS) and overall survival (OS) were not reached.
In 28 patients who received Carteyva, any grade and severe (grade≥3) cytokine release syndrome (CRS) were 42.9% and 0%, respectively, and any grade and severe (grade≥3) neurotoxicity (NT) were 17.9% and 3.6%, respectively.
Dr. Mark J. Gilbert, Chief Medical Officer of JW Therapeutics, commented: "Most patients with r/r FL remain incurable and eventually relapse or progress. Results from this pivotal study provide evidence that Carteyva can result in high tumor remission rates and a manageable toxicity profile in r/r FL patient. Encouraged by these findings, we are looking forward to expanding the indications of Carteyva use into r/r FL, hopefully benefiting more patients soon."
Reference:
Song, Y. et.al.; 63rd Annual ASH (Free ASH Whitepaper) Meeting, 2021, abstract #2434, Atlanta, GA December 10th-14th
About Relmacabtagene Autoleucel Injection (trade name: Carteyva)
Relmacabtagene autoleucel injection (abbreviated as relma-cel, trade name: Carteyva) is an autologous anti-CD19 CAR-T cell immunotherapy products that was independently developed by JW Therapeutics based on a CAR T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company). The first product of JW Therapeutics, relma-cel was approved by the China National Medical Products Administration (NMPA) in September 2021 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, it is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, granted priority review and breakthrough therapy designations.